Head and Neck Tumor Cells Exhibit Altered Proliferation upon Overexpression of nm23 Genes by Maja Herak Bosnar et al.
Head and Neck Tumor Cells Exhibit Altered Proliferation
upon Overexpression of nm23 Genes
Maja Herak Bosnar,a,* Klara Dubrav~i},b Ru`ica Bago,a and Jasminka Paveli}a
a
Division of Molecular Medicine, Ru|er Bo{kovi} Institute, Bijeni~ka cesta 54, P. O. Box 180, HR-10002 Zagreb, Croatia
b
Division of Immunology, Clinical Hospital »Rebro«, Ki{pati}eva 12, HR-10000 Zagreb, Croatia
RECEIVED MARCH 30, 2007; REVISED SEPTEMBER 19, 2007; ACCEPTED OCTOBER 20, 2007
nm23 was identified as a metastasis suppressor gene but is also appointed to a number of other
biological functions. The goal of this study was to reveal the influence of ectopic expression of
nm23-H1 and nm23-H2 on proliferation properties of head and neck tumor cells. The prolifera-
tion rate of transfected cells was evaluated using EGFP reporter system and flow cytometry.
HEp-2 and CAL 33 cells transiently transfected with nm23 cDNA containing constructs exhi-
bited enhanced proliferation. CAL 27 cells constitutively expressing GFP-Nm23-H2 protein,
exhibited intense proliferation the first day after seeding, while the GFP-Nm23-H1 expressing
clone started to proliferate after one-day lag period. The results on transiently transfected HEp-2
and CAL 33 cells generally confirmed previous findings connecting nm23 expression with al-
tered proliferation of head and neck tumors. We speculate that the effects observed on stably
transfected CAL 27 clones are due to their different attachment properties.
Keywords
nm23









Nm23-H1 and Nm23-H2 are subunits of a well known,
»old« enzyme – nucleoside-diphosphate kinase (NDPK),
whose role is to transfer the terminal phosphate from ATP
to all other NDPs and dNDPs.1 Until today, eight mem-
bers of the nm23 gene family have been discovered.2
There are more than few indications that nm23-H1,
nm23-H2 and, possibly, some other members of the fa-
mily have other functions in the cell being linked to cell
differentiation and/or formation of metastases of different
tumors. It seems that low expression of nm23-H1 leads
to metastases formation in breast3,4 and cervical5 carci-
nomas, melanomas6 and several other neoplastic lesions.7
On the other hand, several papers suggest that more in-
vasive hematopoietic tumors exhibit overexpression of
nm23.8,9 There are also tumors in which no correlation
with nm23 and tumor size, differentiation and stage could
be found.7,10,11,12 Apart from their involvement in tumo-
rigenesis and metastasis formation in certain tumors, nm23
genes/proteins have been associated with several distinct
biological processes: microtubule polymerization,13 ve-
sicular trafficking,14 and signal transduction.15 They have
also been found to participate in differentiation and de-
velopment of several species. For instance, inactivation
of Drosophila analogue of nm23 gene leads to abnormal
larval development,16 while experiments on mice embryos
revealed the role of nm23 in development of tissues dur-
ing prenatal period.17 Furthermore, from the work of Po-
stel et al. it has been suggested that Nm23-H2 acts as a
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transcriptional factor for c-myc oncogene.18 Therefore,
many authors propose a multifunctional and tissue spe-
cific nature of, at least some, of the Nm23 proteins.
Previous results of our laboratory,19 based on nm23-
H1 expression correlated with SCCHN (squamous cell
carcinoma of the head and neck) tumor stages and cell
proliferation indicate that nm23-H1 is involved in pro-
gression of SCCHN in a manner, which is not consistent
with its proposed role as a metastasis suppressor gene. Se-
veral other authors exhibited contradictory results.20,21,22
Our main goal was to reveal possible changes of the cell
cycle of benign and malignant head and neck tumor cell
lines upon ectopic expression of nm23-H1 and nm23-H2.
Taken generally, the results confirm our previous find-
ings connecting high levels of Nm23 proteins with head
and neck tumor cell proliferation. However, they also
bring up a number of questions concerning its multi-
functional role in the cell and its potential influence on
cell adhesion.
EXPERIMENTAL
Cells and Culture Conditions
Human head and neck tumor cell lines HEp-2 (squamous
cell carcinoma of the larynx, ATCC), CAL 33 (epithelioma
of the tongue), and CAL 27 (squamous cell carcinoma of
the tongue, both obtained by courtesy of Dr. Jeannine Gio-
anni, Centre Antoine Lacassagne, Nice, France) were cul-
tured in Dulbecco’s modified Eagle medium (DMEM; Life
Technologies) supplemented with 10 % fetal bovine serum
(FBS; Life Technologies), 2 mmol dm–3 glutamine, 100 U ml–1
penicillin (1 U ml–1  1 mg ml–1) and 100 mg ml–1 strepto-
mycin in a humidified chamber with 5 % CO2, at 37 °C.
Constructs and Cloning
nm23-H1 and nm23-H2 full-length cDNA fragments were
subcloned from pcDNA3nm23 constructs (obtained by cour-
tesy of Dr. Marie-Lise Lacombe, Faculte de Medecine Saint
Antoine, Paris, France) into pEGFPC1 (Clontech Lab. Inc.)
minding the open reading frame. Cloning was analyzed by
a set of restriction endonucleases while the existence of fu-
sion GFP-Nm23 proteins was verified by Western blotting.
Western Blot Analysis
Total cell lysates were prepared by resuspending cells in ly-
sis buffer (50 mmol dm–3 Hepes pH = 7.5, 150 mmol dm–3
NaCl, 1 mmol dm–3 EDTA, 1 mmol dm–3 EGTA, 10 % glyce-
rol, 1 % Triton X-100, 1 mmol dm–3 orthovanadate, 2 mg ml–1
leupeptin, 1 mg ml–1 aprotinin) for three minutes on ice. The
cell debris was removed by centrifugation for 15 minutes at
13000 g and 4 °C. Total protein concentration was measured
by Bradford assay against a standard curve of known BSA
(bovine serum albumin) concentrations. Equal amounts of
samples (50 mg of total protein) were loaded on SDS-PAGE
(5 % stacking, 10 % running gel) and electrotransferred to
an Imobilon-PSQ membrane (Millipore). To assess the ex-
pression of endogenous (native) Nm23-H1 and Nm23-H2
proteins in HEp-2, CAL 33 and CAL 27 cell lines, as well
as the existence of fusion GFP-Nm23 proteins, affinity pu-
rified polyclonal antibodies against human Nm23-H1 (ob-
tained by courtesy of Dr. Marie-Lise Lacombe, and prepar-
ed as described by Phung-Ba Pinon et al.23) and polyclonal
antibodies against human Nm23-H2 (obtained by courtesy
of Dr. Ioan Lascu, Universite de Bordeaux-2, Bordeaux,
France) were used. Protein bands were visualized using BM
Chemiluminiscence blotting substrate-POD (Roche) on Lu-
mi-Film-Chemiluminiscent Detection Film (Roche).
Transient Transfection and Sample Preparation
8  105 cells (HEp-2 and CAL 33) were seeded on six-well
plates 24 hours prior to transfection. The cells were trans-
fected (lipofected) with 2.5 mg of plasmid DNA using Lipo-
fectamine Plus Reagent (Life Technologies) according to
manufacturer’s instructions. In cotransfection experiments the
cells were transfected with plasmid DNA in the ratio 2:1
(pcDNA3 : pEGFPC1, respectively).
Forty-eight hours post transfection the cells were tripsi-
nized, centrifuged at 1200 g, and washed twice in phospha-
te-buffered saline (PBS). For cell cycle analysis the cells were
prepared according to a protocol based on several described
methods.24,25 In brief, cells were fixed in 1 % paraformal-
dehyde in PBS for one hour at +4 °C and permeabilized
overnight in 80 % ethanol in PBS. After RN-ase treatment
(100 mg ml–1) and propidium-iodide staining (20 mg ml–1)
for 30 minutes at 37 °C, the cells were stored at +4 °C until
further analysis.
Stably Transfected Cell Line Preparation
CAL 27 cells were seeded on a 100 mm Petri dish and incu-
bated until 80 % confluence. The cells were transfected with
pEGFPC1, pEGFPC1-nm23-H1 and pEGFPC1-nm23-H2
constructs using Lipofectamine Plus Reagent according to
manufacturer’s instructions. Twenty-four hours post trans-
fection the cells were tripsinized, resuspended in 1:20 ratio
in DMEM supplemented with 600 mg/ml geneticin (Sigma),
and seeded in six-well plates. The antibiotic supplemented
medium was changed every 3–4 days until the development
of stabile, resistant colonies. Several clones were established
for every construct used. The presence of fusion GFP-Nm23
proteins in established clones was verified by fluorescent mi-
croscopy and Western blotting.
For cell cycle analysis 1  106, 8  105 and 4  104
cells of each established clone were seeded on six-well pla-
tes and collected by tripsinization after 24, 48 and 72 hours,
respectively. The samples were prepared as described for
transiently transfected cell lines. All established clones were
analyzed but results were displayed for only one, represen-
tative clone per each construct.
Flow Cytometry
Samples were analyzed on FACScan flow cytometer (Bec-
ton Dickinson) equipped with a 15 mW air-cooled 488-nm
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argon-ion laser. For transiently transfected cells total amount
of (10–20)  103 green cells (depending upon efficiency of
transfection) was collected. FL2/FL1 plot was used to se-
parate the transfected (green) cells from nontransfected cells.
Red fluorescence (FL2) was displayed on a linear, and green
fluorescence (FL1) on a log scale. The gate was set to ana-
lyze the cell cycle distribution of »dim« cells. The stably
transfected clones were displayed and gated for cell cycle
analysis on FL2 width vs. FL2-area plot to exclude aggre-
gates. Data were analyzed using CellQuestTM software (Bec-
ton Dickinson), ModFit LTTM 2.0 (Verity Software House)
and WinMDI27. The results of cell cycle distribution analy-
sis of transiently transfected cells are shown as the mean of
three experiments with standard deviation. In the case of
stably transfected clones, we presented the mean of two ex-
periments with standard deviation.
Growth Rate
The growth rate of pEGFP-nm23 stably transfected CAL 27
clones was established according to the results of the MTT
test (Sigma) which was preformed every 24 hours in a
period of six days after seeding.26 The results represent one
of three repeated experiments.
RESULTS
Cell Extracts from All Cell Lines Analyzed
Exhibited Nm23-H1, Nm23-H2 and GFP-Nm23
Fused Proteins
After Western blot analysis with anti-nm23-H1 and anti-
nm23-H2 antibodies HEp-2, CAL 33 and CAL 27 cell
lines all exhibited endogenous (native) Nm23-H1 and
Nm23-H2 proteins as seen in Figure 1. To prove the ex-
istence of fusion GFP-Nm23 proteins HEp-2 cells were
transiently transfected. Figure 2 shows bands of about 51
kDa in size, which indicate the existence of fusion GFP-
Nm23-H1 and GFP-Nm23-H2 proteins. Figure 3 shows
the expression of GFP-Nm23-H1 in stably expressing
CAL 27 cells.
nm23 Overexpressing Constructs Upregulate
Proliferation in Transiently Transfected HEp-2 and
CAL 33 Cells
Flow cytometry experiments were conducted to verify the
influence of nm23 overexpression on the cell cycle of
HEp-2 (Figure 4) and CAL 33 (Figure 5) head and neck
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Figure 1. Expression of endogenous Nm23 proteins in head and
neck tumor cell lysates. Western blot analysis using: a) anti-Nm23-
H1 antibodies. b) anti-Nm23-H2 antibodies. Lane 1: HEp-2; lane
2: CAL 33; lane 3: CAL 27.
Figure 2. Expression of GFP-Nm23-H1 and GFP-Nm23-H2 pro-
teins in transiently transfected HEp-2 cell lysates. Western blot ana-
lysis using: a) anti-Nm23-H1 antibodies. Lane 1: pEGFPC1-nm23-
H1 transfected cells; lane 2: pEGFPC1-nm23-H2 transfected cells;
b) anti-Nm23-H2 antibodies. Lane 1: pEGFPC1-nm23-H1 trans-
fected cells; lane 2: pEGFPC1-nm23-H2 transfected cells.
Figure 3. Expression of GFP-Nm23-H1 in stably transfected CAL
27 cell lysates. Western blot analysis using anti-Nm23-H1 anti-
bodies. Lanes 1, 2 and 3 represent three different stabile clones
constitutively expressing GFP-Nm23-H1 (upper band). The lower
band represents the endogenous Nm23-H1.
Figure 4. Cell cycle distribution of transiently transfected HEp-2
cells. K: untransfected HEp-2 cells; C1: pEGFPC1 transfected cells;
H1: pEGFPC1-nm23-H1 transfected cells; H2: pEGFPC1-nm23-H2
transfected cells; (C1+H1): pEGFPC1 and pcDNA3-nm23-H1
cotransfected cells; (C1+H2): pEGFPC1 and pcDNA3-nm23-H2
cotransfected cells. Results represent mean ± SD.
Figure 5. Cell cycle distribution of transiently transfected CAL 33
cells. K: untransfected CAL 33 cells; C1: pEGFPC1 transfected cells;
H1: pEGFPC1-nm23-H1 transfected cells; H2: pEGFPC1-nm23-
H2 transfected cells; (C1+H1): pEGFPC1 and pcDNA3-nm23-H1
cotransfected cells; (C1+H2): pEGFPC1 and pcDNA3-nm23-H2
cotransfected cells. Results represent mean ± SD.
tumor cells in vitro. For that purpose, the cells were trans-
fected and cotransfected with a series of constructs
and combinations of constructs (pEGFPC1 as control,
pEGFPC1-nm23-H1, pEGFPC1-nm23-H2, pEGFPC1 +
pcDNA3-nm23-H1 and pEGFPC1 + pcDNA3-nm23-H2),
whereas untransfected cells and the cells transfected with
pEGFPC1 were used as controls. Cell cycle analysis was
performed 48 hours post transfection. The results indi-
cate that cells transiently transfected with pEGFPC1-nm23
constructs stimulate the proliferation of HEp-2 and CAL
33 cells in culture, although the results were not statisti-
cally significant according to Student’s t-test (P>0.05).
Figure 4 shows an increase in the number of HEp-2 cells
(cca. 7–10 %) in S/G2/M compartment in pEGFPC1-nm23
transfected cells, if compared to untransfected cells and
the cells transfected with the »empty« vector. The in-
crease of the number of proliferating HEp-2 and CAL 33
cells was more convincing in cotransfection experiments
where the results were statistically significant with a
P<0.05. The results exhibit an increased number of
proliferating transfected and cotransfected cells, the only
exception being the pEGFPC1-nm23-H1 transfected cells,
which show minimal proliferation effect compared to cells
transfected with the »empty« vector. The portion of HEp-2
proliferating cells in cotransfection experiments were cca.
10 %, while the number of CAL 33 proliferating cells in-
creased more than 15 % compared to the »empty« vector
transfected cells).
Stably Transfected CAL 27 Cells Exhibit Different
Patterns in Proliferation Activity
To evaluate the influence of GFP-Nm23 proteins on cell
growth in culture, we analyzed the growth rate of stably
transfected clones during the period of six days (Figure
6). We analyzed several stabile clones but we displayed
only one representative clone for each construct: GFP-
Nm23-H1 clone (K49), GFP-Nm23-H2 clone (K71),
pEGFPC1 clone (K78). We also analyzed the growth rate
of untransfected cells. The major difference in growth rate
between the mentioned clones was visible 24 hours after
seeding. It was clear that the K71 clone went immedia-
tely into proliferation and almost doubled, while the K49
clone barely started proliferating. This result was in con-
cordance with our visual observation that cells overex-
pressing GFP-Nm23-H1 after more than 24 hours did not
acquire the expected epithelial morphology and were still
completely spherical in contrast to the cells overexpres-
sing GFP-Nm23-H2 (data not shown). The flow cytometry
experiments completely confirmed these observations
(Figure 7). The difference in cell cycle distribution 24
hours after seeding clearly indicated that Nm23-H1
expressing clone (K49) hardly started to proliferate (28
% of cells in S, and none in G2/M phase) in contrast to
more than 65 % S-phase cells, and 12 % G2/M-phase
cells in Nm23-H2 expressing clone. GFP clone (K78), as
well as the untransfected cells, displayed cell cycle dis-
tribution somewhere between those two extremes. The
results are statistically significant, P<0.05. Seventy-two
hours after seeding all clones adopt the same cell cycle
distribution.
DISCUSSION
During the last decade, it has been suggested that Nm23
proteins regulate a number of cellular processes although
the underlying mechanisms of these processes have not
yet been revealed. Several authors have studied the in-
fluence of nm23 genes on proliferation, differentiation
or potential invasiveness of head and neck tumor cells.
Takes et al. studied the expression of several oncogenes
and tumor suppressor genes in squamous cell carcinoma
of the larynx, pharynx and the oral cavity.20 The study
failed to prove any difference in expression of nm23 in
tumor compared to normal tissue. In the work of Gun-
duz et al. overexpression of Nm23 protein was found in
the majority of primary tumors compared to corresponding
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Figure 6. Growth curves of CAL 27 cell stable transfected with
pEGFP-nm23 constructs. Growth curves were obtained using MTT
test. Clone K49: cells stable transfected with pEGFPC1-nm23-H1;
clone K71: cells stable transfected with pEGFPC1-nm23-H2; clone
K78: cells stable transfected with »empty« (pEGFPC1) vector.
Figure 7. Cell cycle distribution of CAL 27 clones. K: untransfect-
ed cells; clone K78: cells transfected with pEGFPC1; clone K49:
pEGFPC1-H1 transfected cells; clone K71: pEGFPC1-nm23-H2
transfected cells. I, II, III: 24, 48, 72 hours after seeding, respecti-
vely. Results represent mean ± SD.
normal mucosa, while decreased expression was asso-
ciated with poor differentiation and distant metastases.21
Our study was conducted to evaluate the role of nm23-
H1 and nm23-H2 on the cell cycle of head and neck tu-
mor cells in vitro, and to confirm our previous studies
that connected tumor progression of SCCHN with over-
expression of nm23-H1. The major goal was to reveal the
possible differences in cell cycle distribution arising upon
ectopic expression of GFP-Nm23 or Nm23 proteins in cells
originating from benign (CAL 33) vs. malignant (HEp-2)
tumors. The malignant CAL 27 cells used in preparing
stabile clones, unfortunately weren’t suitable for transient
transfection experiments by flow cytometry due to low
transfection efficiency (less than 2 %, compared to 16–
20 % for HEp-2 cells, and 3–5 % for CAL 33 cells; data
not shown).
Although being a handy technique for detecting the
efficiency of transfection and exogenous protein produc-
tion, proteins fused with reporter genes/proteins often lose
a portion of their efficiency. To overcome the possible
problems concerning this issue, we performed cotransfec-
tions with pEGFPC1 as a transfection marker, and nm23
cDNAs introduced in pcDNA3 which produced a recom-
binant, but native protein.
Our results brought up several interesting points. All
three cell lines expressed endogenous Nm23-H1 and
Nm23-H2 proteins, which was expected according to
numerous former studies confirming that most cell lines
and tissues, especially of epithelial origin, express Nm23/
NDPK in abundance. Therefore, we presume that the ef-
fects concerning proliferation rate were due to overex-
pression. As can be seen in Figures 4 and 5, a slight in-
crease in proliferation rate is present in cells transfected
with the »empty« vector in both cell lines. This observa-
tion was, also, observed elsewhere,27 but in our case this
increase in cell proliferation rate was not statistically sig-
nificant. In our experiments, we observed an increased
number of nm23 transfected cells in S/G2/M phase com-
pared to control the only exception being GFP-nm23-H1
expressing CAL 33 cells which displayed no marked
proliferation. However, the increase of the proliferation
rate is not considered significant in the cells transfected
with the pEGFPC1-nm23 constructs but it is significant
in cotransfection experiments. We presume that this is due
to the fact that fusion GFP-Nm23 proteins are less active
compared to native recombinant Nm23 proteins. The
change in the proliferation rate of CAL 33 cells tran-
siently transfected with pEGFPC1 + pcDNA3-nm23-H1
was cca. 15 %, and statistically significant (P<0.01). One
of the possible explanations for proliferation increase
comes from the work of Cipollini et al.28 in which the
authors state that Nm23 proteins are most abundantly
expressed in S phase of breast cancer cells. It is, there-
fore, possible that the cells recognize Nm23 overexpres-
sion as a signal to enter the S phase.
Taking into consideration a number of previous stu-
dies connecting nm23 overexpression and cell growth and
tumorigenesis,29,30 as well as the results obtained in our
laboratory, the proliferation effect in nm23 transiently
transfected SCCHN tumor cell lines was expected. In this
part, our findings confirm our previous study on SCCHN,
and broaden them on nm23-H2 gene. One may consider
this increase in proliferation too small to be considered
significant. However, it must be emphasized that the cells
analyzed in this work are highly proliferating tumor cells,
and that an increase in the number of proliferating cells
of over 15 %, as in some cases, is noteworthy. Since it is
not recommended to compare the cell-cycle distribution
of cells with different fluorescence intensity (»bright« and
»dim«), we analyzed only »dim« cells, i.e. cells with low-
er fluorescence intensity (lower GFP expression level),
because the number of »bright« cells was significantly
lower. It is possible that by analyzing »bright« cells, a
higher proliferation rate would have been obtained. A
difference in proliferation rate due to overexpression of
nm23 genes could be observed between HEp-2 and CAL
33 cells. The number of HEp-2 cells in the S/G2/M com-
partment increased 7–10 % due to overexpression of
nm23 genes, while the number of proliferating CAL 33
cells increased for cca. 15 %. In the work of Cipollini et
al.31 and Caligo et al.32 similar effects were observed,
but on a different model system (breast carcinoma cells).
Their results suggested the role of Nm23-H1 in cell pro-
liferation, but the involvement of Nm23-H1 was dimi-
nished in highly metastatic cells. The authors hypothe-
sized that nm23 might be essential for cell proliferation,
but could also be an inhibitor of proliferation via a ne-
gative feedback mechanism. They also find it possible that
cells with a highly invasive phenotype find alternative
proliferating pathways. One should also bear in mind that
Nm23-H1 and Nm23-H2 form several isoenzymes of the
NDPK, that they exhibit a different expression rate in dif-
ferent tissues and organs and, possibly, distinct functions
in different cancer types. Therefore, the reason why more
invasive HEp-2 cells are less sensitive to Nm23 increase
than CAL 33 cells, is highly speculative at this point.
Several authors described the behavior of head and
neck tumor cells upon changing the expression level of
nm23 genes. Miyazaki et al.33 described the unusual be-
havior of nm23-H2 transfected cells of the oral cavity.
The cells didn’t differ morphologically from untransfect-
ed cells, but they proliferated faster, became less serum
dependent and lost responsiveness to growth factor and
thus, suppressed metastatic activity. nm23-H1 transfected
cells did not exhibit this feature. On a slightly different
model, on cultured keratinocytes, it was shown that, al-
though not showing direct proliferation enhancement in
monoculture, nm23-H2 transfectants do form highly pro-
liferating epithelium in three-dimensional organotypic cul-
ture.34 The authors also suggest that the expression ratio
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of nm23-H1 / nm23-H2 is responsible for proliferation
behavior. Taking all these findings into account, it would
be interesting to observe the effect of cotransfection of
both nm23 genes in our model system and to verify the
results on in vitro raft cultures. Taken generally, our re-
sults partly confide with the results of other investiga-
tors. We are, however, aware of the shortcomings of our
method that originate in low transfection rates, and a too
low number of different cell lines taken into analysis.
Our results should be confirmed by another independent
method, for instance staining the cells with BrdU or some
other independent indicator of cell proliferation. On the
other hand, we observed changes that had arisen upon
enhanced expression of already expressed genes/proteins
in the cell. It is debatable whether overexpression brings
any quantitative or qualitative difference in the cells al-
ready expressing the gene of interest. Although we do not
doubt that the finely tuned cellular processes sense the
2-fold overexpression of nm23 genes, the true confirma-
tion would come from silencing the endogenous genes
by introducing siRNA. However, this may be the object
of future experiments.
Growth rate curves and flow cytometry experiments
on stably transfected clones confirmed our visual obser-
vation (data not shown) that GFP-Nm23-H1 expressing
cells (K49) need sufficient time to start proliferating af-
ter seeding. This is different from GFP-Nm23-H2 (K71)
clone that starts to proliferate shortly after seeding. Sin-
ce nm23 is probably involved in cell attachment, either
directly by possessing the RGD sequence typical for in-
tegrin binding proteins2 or indirectly, we hypothesized that
different proliferation properties of transfected clones
could be a consequence of their different attachment
properties. Namely, since GFP-Nm23-H1 expressing clone
needs a longer time to attach to the surface of the dish, it
is to be expected that these cells would start proliferating
at a later time point, than the immediately attaching GFP-
Nm23-H2 expressing clone. Three days after seeding,
the proliferation time seems to equalize between the two
clones and also compared to controls. It may seem that
the results obtained on stabile transfected clones are not
in accordance with the ones obtained on transient trans-
fections, but it must be clear that these two experiments
were designed and conducted differently. In transient
transfections, we first seeded the cells and analyzed
them 48 hours post transfection, while stably transfected
cells already constitutively expressed GFP-Nm23 pro-
teins when seeded. Recent findings of Fournier et al.35
presented new evidence connecting Nm23 proteins with
molecules involved in cell attachment, so our further ex-
periments will be focused on revealing the mechanisms
through which Nm23 proteins influence proliferation.
We also intend to study the relation of these proteins to
cell-surface and cell-cell adhesion molecules in head and
neck tumor cells.
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SA@ETAK
Stanice tumora glave i vrata pokazuju promijenjen profil proliferacije
pod utjecajem poja~ane ekspresije gena nm23
Maja Herak Bosnar, Klara Dubrav~i}, Ru`ica Bago i Jasminka Paveli}
Gen nm23 prvi je otkriveni supresor metastaziranja, a usporedo s tim, dodijeljeno mu je jo{ nekoliko bio-
lo{kih funkcija. Cilj ovog rada bio je otkrivanje utjecaja poja~ane ekspresije gena nm23-H1 i nm23-H2 na pro-
liferaciju stanica tumora glave i vrata in vitro. Stupanj proliferacije transfeciranih stanica odre|en je upotrebom
reporterskog sustava EGFP uz pomo} proto~ne citometrije. Stanice HEp-2 i CAL 33 prolazno transfecirane
konstruktima koji sadr`e cDNA gena nm23 pokazale su poja~anu proliferativnu aktivnost. Stanice CAL 27 koje
konstitutivno imaju GFP-NM23-H2 pokazuju intenzivnu proliferaciju prvi dan nakon nasa|ivanja, dok stanice
koje imaju GFP-Nm23-H1 zapo~inju proliferaciju s jednim danom zaka{njenja. Rezultati na prolazno trans-
feciranim stanicama HEp-2 i CAL 33, op}enito uzev{i, potvrdile su dosada{nja istra`ivanja na tumorima glave i
vrata. Pretpostavlja se da su rezultati dobiveni na stabilno transfeciranim klonovima stanica CAL 27 posljedica
njihovih razli~itih osobina vezanih za prianjanje uz podlogu.
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